Amphastar pharmaceuticals reports financial results for the three months and full-year ended december 31, 2022

Reports net revenues of $135.0 million for the three months ended december 31, 2022 rancho cucamonga, ca / accesswire / february 28, 2023 / amphastar pharmaceuticals, inc. (nasdaq:amph) ("amphastar" or the "company") today reported results for the three months and full-year ended december 31, 2022. fourth quarter highlights net revenues of $135.0 million for the fourth quarter gaap net income of $33.9 million, or $0.66 per share, for the fourth quarter adjusted non-gaap net income of $37.6 million, or $0.73 per share, for the fourth quarter full-year highlights net revenues of $499.0 million for the fiscal year gaap net income of $91.4 million, or $1.74 per share, for the fiscal year adjusted non-gaap net income of $103.2 million, or $1.97 per share, for the fiscal year dr. jack zhang, amphastar's president and chief executive officer, commented: "we are pleased to report our strongest quarter yet, driven by sales of epinephrine, primatene mist®, glucagon, and other finished pharmaceutical products.
AMPH Ratings Summary
AMPH Quant Ranking